Role of Ribomunyl® in the Prevention of Recurrent Respiratory Tract Infections in Adults

[1]  U. Ramstedt,et al.  NK-cell stimulating properties of a membrane proteoglycane from non-capsulated Klebsiella pneumoniae biotype a. , 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section C, Immunology.

[2]  R. Rylander,et al.  Airways inflammation among workers in poultry houses , 2006, International archives of occupational and environmental health.

[3]  L. Peterson.  Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance , 2005, Clinical Microbiology and Infection.

[4]  A. Torres,et al.  Guidelines for the management of adult lower respiratory tract infections , 2005, European Respiratory Journal.

[5]  L. Nielsen,et al.  Generation and Maturation of Dendritic Cells for Clinical Application Under Serum-Free Conditions , 2005, Journal of immunotherapy.

[6]  I. J. van Vlodrop,et al.  Th1-Polarizing Capacity of Clinical-Grade Dendritic Cells Is Triggered by Ribomunyl but Is Compromised by PGE2: The Importance of Maturation Cocktails , 2005, Journal of immunotherapy.

[7]  D. C. Sullivan,et al.  Vancomycin-Tolerance among Clinical Isolates of Streptococcus pneumoniae in Mississippi during 1999-2001 , 2005, The American journal of the medical sciences.

[8]  R. Akins,et al.  Gram‐Positive Resistance: Pathogens, Implications, and Treatment Options Insights Society of Infectious Diseases Pharmacists , 2005, Pharmacotherapy.

[9]  A. Devillers,et al.  Biodistribution of radiolabelled human dendritic cells injected by various routes , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  Pascale Jeannin,et al.  Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. , 2005, Immunity.

[11]  Y. Delneste,et al.  Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production. , 2004, Blood.

[12]  A. Šedivá,et al.  Maturation of dendritic cells by bacterial immunomodulators. , 2004, Vaccine.

[13]  J. Bonnefoy,et al.  Outer membrane protein A (OmpA): a new pathogen-associated molecular pattern that interacts with antigen presenting cells-impact on vaccine strategies. , 2002, Vaccine.

[14]  J V West,et al.  Acute upper airway infections , 2002, British medical bulletin.

[15]  J. Abastado,et al.  Identification of a Clinical-Grade Maturation Factor for Dendritic Cells , 2002, Journal of immunotherapy.

[16]  J. Bonnefoy,et al.  Targeting of Nasal Mucosa-Associated Antigen-Presenting Cells In Vivo with an Outer Membrane Protein A Derived from Klebsiellapneumoniae , 2001, Infection and Immunity.

[17]  N. Kadowaki,et al.  Subsets of Human Dendritic Cell Precursors Express Different Toll-like Receptors and Respond to Different Microbial Antigens , 2001, The Journal of experimental medicine.

[18]  K. Agren,et al.  The nasopharynx and the middle ear. Inflammatory reactions in middle ear disease. , 2000, Vaccine.

[19]  P. Romero,et al.  OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway , 2000, Nature Immunology.

[20]  S. Kernéis,et al.  Translocation of Ribosomal Immunostimulant Through an In Vitro–Reconstituted Digestive Barrier Containing M-Like Cells , 2000 .

[21]  R. Wilson.  Evidence of bacterial infection in acute exacerbations of chronic bronchitis. , 2000, Seminars in respiratory infections.

[22]  T. Baussant,et al.  Cutting Edge: Outer Membrane Protein A (OmpA) Binds to and Activates Human Macrophages , 2000, The Journal of Immunology.

[23]  N. Pride,et al.  Recent trends in physician diagnosed COPD in women and men in the UK , 2000, Thorax.

[24]  T. Baussant,et al.  Carrier Properties of a Protein Derived from Outer Membrane Protein A of Klebsiella pneumoniae , 1999, Infection and Immunity.

[25]  D. Mannino,et al.  Worldwide epidemiology of chronic obstructive pulmonary disease. , 1999, Current opinion in pulmonary medicine.

[26]  J. Collet,et al.  Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. , 1997, American journal of respiratory and critical care medicine.

[27]  B. Schwarz,et al.  An Economic Analysis Using Ribosomal Immunotherapy to Treat Children with Recurrent Upper Respiratory Tract Infections , 1997 .

[28]  P. Cauwenberge,et al.  Effectiveness of ribosomal fractions ofKlebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and the membrane fraction ofKp (Ribomunyl) in the prevention of clinical recurrences of infectious rhinitis , 1997, European Archives of Oto-Rhino-Laryngology.

[29]  J. Debas.  Ribosomal Immunostimulation in the Prevention of Recurrent Amygdalitis , 1997, Drugs.

[30]  J. Allaire,et al.  Kinetics of specific salivary IgA responses in man after oral challenge by ribosomal immunostimulant. , 1997, International journal of immunopharmacology.

[31]  C. Mallett,et al.  Protection against local Shigella sonnei infection in mice by parenteral immunization with a nucleoprotein subcellular vaccine , 1995, Infection and immunity.

[32]  M. Béné,et al.  Bacterial crude extracts or ribosomes are recognized similarly by peripheral and mucosal B cells. , 1994, FEMS immunology and medical microbiology.

[33]  B. Balbi,et al.  Lower respiratory tract inflammation in chronic bronchitis. Evaluation by bronchoalveolar lavage and changes associated with treatment with Immucytal, a biological response modifier. , 1994, Chest.

[34]  M. Béné,et al.  Antibody-producing cells in peripheral blood and tonsils after oral treatment of children with bacterial ribosomes. , 1994, International journal of immunopharmacology.

[35]  M. Béné,et al.  Bacterial Lysates and Ribosomes as Inducers of Specific Immune Responses: a Comparative Study , 1993, Scandinavian journal of immunology.

[36]  C. Roques,et al.  In vitro stimulation of polymorphonuclear cell adhesion by ribomunyl and antibiotic + ribomunyl combinations: effects on CD18, CD35 and CD16 expression. , 1993, International journal of immunopharmacology.

[37]  A. Kantar,et al.  Effect of Oral Administration of Bacterial Extracts on the Bactericidal Capacity of Polymorphonuclear Leucocytes in Children with Recurrent Respiratory Infections , 1991, The Journal of international medical research.

[38]  B. Klein,et al.  Bacterial ribosomal immunostimulants prime alveolar macrophages in vivo to produce interleukin 1 in vitro. , 1991, Chest.

[39]  M. Calvani,et al.  Clues to the Mechanism of Action of Acetyl-L-Carnitine in the Central Nervous System , 1991 .

[40]  T. Thom.  International comparisons in COPD mortality. , 1989, The American review of respiratory disease.

[41]  J. Revillard,et al.  Induction of Murine B Cell Proliferation and Immunoglobulin Synthesis by Some Bacterial Ribosomes , 1988, Microbiology and immunology.

[42]  R. Gregory.  Microbial ribosomal vaccines. , 1986, Reviews of infectious diseases.

[43]  W. Johnson,et al.  Immunogenicity of Ribosomal Vaccines Isolated from Group A, Type 14 Streptococcus pyogenes , 1975, Infection and immunity.

[44]  G. Youmans,et al.  Immunogenic Activity of a Ribosomal Fraction Obtained from Mycobacterium tuberculosis , 1965, Journal of bacteriology.

[45]  C. Donner.  Acute exacerbation of chronic bronchitis: need for an evidence-based approach. , 2006, Pulmonary pharmacology & therapeutics.

[46]  J. Bystroň,et al.  Effect of Ribosomal Immunotherapy on the Clinical Condition and Plasma Levels of Cytokines IL-4, IL-5, IL-12 and IFNγ and Total IgE in Patients with Seasonal Allergy during the Pollen Season , 2004, Clinical drug investigation.

[47]  N. Corvaïa,et al.  Inhibition of immunoglobulin e synthesis by a membrane fraction from Klebsiella pneumoniae (FMKP) , 2002 .

[48]  J. Collet,et al.  Economic impact of using an immunostimulating agent to prevent severe acute exacerbations in patients with chronic obstructive pulmonary disease. , 2001, Canadian respiratory journal.

[49]  F. Ottaviani,et al.  Efficacy and tolerability of immucytal® in the prevention and treatment of respiratory tract infections in adults: A randomized, placebo-controlled, double-blind study , 2001 .

[50]  P. Tarsia,et al.  Clinical efficacy of a vaccine-immunostimulant combination in the prevention of influenza in patients with chronic obstructive pulmonary disease and chronic asthma. , 1997, Journal of chemotherapy.

[51]  M. Béné,et al.  Specific antibody-producing cells in humans after oral immunization with a ribosomal vaccine Ribomunyl. , 1995, Advances in experimental medicine and biology.

[52]  H. Binz,et al.  Ribosomes as carriers for antigenic determinants of the surface of micro-organisms. , 1992, Developments in biological standardization.

[53]  C. Roques,et al.  Immunostimulant effects on granulocyte functions during an acute respiratory infection. , 1992, Developments in biological standardization.

[54]  A. Mantovani,et al.  Chemotactic cytokine gene expression and production induced in human monocytes by membrane proteoglycans from Klebsiella pneumoniae. , 1991, International journal of immunopharmacology.

[55]  Nikolaeva Lv,et al.  Molecular-biological and immunological properties of ribosomal vaccines. , 1991 .

[56]  C. Roques,et al.  Effect of an in vivo immunostimulant treatment on PMN functions: interaction with antibiotics in vitro. , 1991, International journal of immunopharmacology.

[57]  A. Sica,et al.  Interleukin-6 gene expression and production induced in human monocytes by membrane proteoglycans from Klebsiella pneumoniae. , 1990, International journal of immunopharmacology.

[58]  N. Graham,et al.  The epidemiology of acute respiratory infections in children and adults: a global perspective. , 1990, Epidemiologic reviews.

[59]  M. Béné,et al.  Increase in specific antibody-forming cells in human tonsils after oral stimulation with D-53, a ribosomal vaccine. , 1990, International journal of immunopharmacology.

[60]  P. Allavena,et al.  Stimulation of cytotoxic and non-cytotoxic functions of natural killer cells by bacterial membrane proteoglycans and ribosomes. , 1989, International journal of immunopharmacology.

[61]  F. Capsoni,et al.  Immunomodulation of polymorphonuclear leukocytes by D53 Immucytal and its constitutive fractions. , 1989, Bollettino dell'Istituto sieroterapico milanese.

[62]  L. Dussourd d'Hinterland,et al.  Ribosomal vaccines: immunological study. , 1980, Arzneimittel-Forschung.